Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
RC
Rocket Pharmaceuticals, Inc. Common Stock
RCKT
Mkt Cap
$238.8M
Volume
1.69M
Next Earnings
November 5th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
RC
RCKT
RC
Rocket Pharmaceuticals, Inc. Common Stock
RCKT
News
·
ROCKET ALERT: Bragar Eagel & Squire, P.C. is Investigating Rocket Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Mkt Cap
$259.1M
Volume
1.69M
Next Earnings
November 5th
Chart
Financials
Earnings
News
About
Insider
Filings
ROCKET ALERT: Bragar Eagel & Squire, P.C. is Investigating Rocket Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Law firm investigating Rocket Pharmaceuticals for potential securities fraud related to undisclosed clinical trial protocol changes and serious adverse events in RP-A501 study, which led to a 37% stock price drop.
GlobeNewswire Inc. · Oct 23, 2025
DEADLINE ALERT for RCKT, DDD, TEM, RDDT: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions
Law firm alerts investors about potential securities fraud class action lawsuits for four companies, alleging misleading statements and undisclosed risks during specific class periods in 2024-2025.
GlobeNewswire Inc. · Aug 11, 2025
RCKT DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Rocket Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 11 Deadline in Securities Class Action – RCKT
Rosen Law Firm alerts Rocket Pharmaceuticals investors about a securities class action lawsuit alleging false statements regarding the effectiveness and safety of drug candidate RP-A501, with an important deadline on August 11, 2025.
GlobeNewswire Inc. · Aug 10, 2025
Deadline Soon: Rocket Pharmaceuticals, Inc. (RCKT) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
Law Offices of Frank R. Cruz alerts investors about an upcoming August 11, 2025 deadline to participate in a securities fraud class action lawsuit against Rocket Pharmaceuticals following an FDA clinical hold on a Danon disease treatment trial after a patient's death.
Benzinga · Aug 8, 2025
MONDAY INVESTOR DEADLINE: Robbins Geller Rudman & Dowd Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Rocket Pharmaceuticals faces a class action lawsuit alleging misleading statements about its Phase 2 clinical trial for RP-A501, with claims of concealing serious adverse events including patient death, which led to an FDA clinical hold and stock price decline.
GlobeNewswire Inc. · Aug 7, 2025
Deadline Alert: Rocket Pharmaceuticals, Inc. (RCKT) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
Rocket Pharmaceuticals faces a class action lawsuit after disclosing an FDA clinical hold on its Danon disease treatment trial following a patient's death, causing significant stock price decline.
GlobeNewswire Inc. · Aug 7, 2025
RCKT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
A class action lawsuit has been filed against Rocket Pharmaceuticals after the FDA placed a clinical hold on its RP-A501 Phase 2 pivotal study following a patient's death, causing the stock price to drop 37% in one trading day.
GlobeNewswire Inc. · Aug 6, 2025
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Rocket Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - RCKT
Pomerantz Law Firm filed a class action lawsuit against Rocket Pharmaceuticals after a patient death in a Phase 2 gene therapy trial, causing the stock to drop 62.84%.
GlobeNewswire Inc. · Aug 5, 2025
Rocket Pharmaceuticals, Inc. (RCKT) Faces Securities Class Action Amid Protocol Change and FDA’s Clinical Hold on Gene Therapy Trial – Hagens Berman
Rocket Pharmaceuticals faces a securities class action lawsuit after the FDA placed a clinical hold on its Phase 2 trial for RP-A501, a gene therapy for Danon disease, causing its stock to drop over 60% on May 27, 2025.
GlobeNewswire Inc. · Aug 4, 2025
מועד אחרון חשוב לתביעה נגד RCKT: רוזן, משרד ארצי מוביל, מעודד משקיעים ב- Rocket Pharmaceuticals, Inc עם הפסדים של יותר מ-100 אלף דולר להבטיח ייעוץ לפני המועד האחרון החשוב של 11 באוגוסט בתביעה ייצוגית בניירות ערך - RCKT
Rosen Law Firm alerts Rocket Pharmaceuticals investors about a securities class action lawsuit alleging false statements about clinical trial effectiveness and safety of drug RP-A501, with an important filing deadline on August 11, 2025.
GlobeNewswire Inc. · Aug 2, 2025
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
RC
RCKT
Rocket Pharmaceuticals, Inc. Common Stock
Buy
Sell
Market
Limit
Soon
RCKT
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any RCKT yet.
Related Tickers
Earnings